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Abstract
Objective. To establish evidence-based and experts’ opinion filtered statements on the optimal treatment choice
between cycling (switch) and changing mode of action strategies (swap) in RA patients failing TNF inhibitors (TNFis).
Methods. The relevant question (switch vs swap) was rephrased into a research question according to the population,
intervention, comparison and outcome (PICO) strategy, considering all the available scientific evidence published from
the 2013 EULAR set of recommendations up to mid-January 2016. Final statements derived from the retrieved scientific
evidence and experts’ consensus, with eventual rephrasing through a Delphi method during a national consensus of
Italian rheumatologists.
Results. From a total of 365 records, 12 studies were finally included. The final statements argued that, until head-to-
head comparison data are available, switch and swap can be still considered suitable strategies in RA patients failing first
TNFi, even though some data seem to lend more support to a different mode of action-targeted strategy.
Conclusion. After failure of first TNFi course, switch and swap can be currently considered as alternative suitable
approaches in RA patients.
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Rheumatology key messages
. RA patients failing first TNFi might benefit from both a cycling and a swapping strategy.
. After failure of first TNFi course, swapping seropositive RA patients to rituximab seems more efficacious.
. Cost-effectiveness evaluation in head-to-head trials should clarify the best option for RA patients after TNFi
failure.
Introduction
Biologic DMARDs (bDMARDs) have dramatically improved
the management of RA patients failing conventional thera-
pies. Several bDMARDs have been approved both as first
and as second line therapies, with a general and actual
trend by rheumatologists of commencing TNF inhibitors
(TNFis) as primary choice, due to the more robust data
on their long-term efficacy and safety compared with
other more recently introduced bDMARDs with different
mode of action (MoA). However, almost 30% of patients
do not respond (or respond suboptimally) to TNFi, failing to
maintain an initially good response over time or experien-
cing adverse events (AEs) leading to treatment discontinu-
ation [1]. Existing recommendations (Table 1), in line with
published scientific data integrated with experts’ opinions,
1Division of Rheumatology, University of Pavia, IRCCS Policlinico San
Matteo Foundation, Pavia, 2Department of Rheumatology, Gaetano
Pini Institute, Milan, 3Department of Emergency and Organ
Transplantation (DETO), University of Bari, Section of Rheumatology,
Bari, 4Rheumatology Department of Lucania, San Carlo Hospital of
Potenza and Madonna delle Grazie Hospital of Matera. Basilicata
Ricerca Biomedica (BRB) Foundation, Potenza, 5Rheumatology Unit,
S. Giovanni di Dio Hospital, Florence, 6Rheumatology Unit, University
Clinic and AOU of Cagliari, Cagliari, 7Rheumatology Service ASL BT 
DSS4 Barletta, 8Fondazione Ospedale San Camillo  Roma,
9Reumatologia Ospedaliera, Dipartimento Internistico, A.O.U. ‘OO.RR’
 Foggia and 10Institute of Rheumatology, Fondazione Policlinico
Universitario Agostino Gemelli, Catholic University of the Sacred Heart,
Rome, Italy
yDeceased.
Correspondence to: Monica Todoerti, Division of Rheumatology,
University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia,
Piazzale Golgi 19, Pavia, Italy.
E-mail: monica.todoerti@gmail.com
Submitted 11 August 2017; revised version accepted 4 June 2018
! The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com
RHEUMATOLOGY Rheumatology 2018;57:vii42vii53doi:10.1093/rheumatology/key195
R
E
V
IE
W
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/57/Supplem
ent_7/vii42/5115901 by D
ivisione C
oordinam
ento Bib. M
ilano user on 12 N
ovem
ber 2019
offer evidence-based flow-charts in cases of failure of one
or more TNFis in RA patients [25]. All these sets of rec-
ommendations agree in suggesting a different MoA
bDMARD when two or more TNFis have failed, recognizing
that efficacy might decline when cycling to a third or fourth
TNFi. On the contrary, in the case of failure of the first TNFi,
no strong evidence seems to support one strategy over
another, so that the therapeutic choice is left to the experi-
ence of the treating physician, who should take into con-
sideration also patient and disease characteristics. In this
setting, switching to a second anti-TNF agent (cycling strat-
egy) or adopting an alternative class of targeted agents
with a different MoA (swapping strategy) might both be
considered as alternative available strategies, but the opti-
mal treatment approach has yet to be defined. In the 2013
and 2016 set of European recommendations from the
EULAR, the corresponding topic similarly states that ‘if a
bDMARD or tsDMARD [targeted synthetic DMARD] has
failed, treatment with another bDMARD or a tsDMARD
should be considered; if one TNF inhibitor therapy has
failed, patients may receive another TNF inhibitor or an
agent with another mode of action’ [3, 5]. Once again, no
standardized approach was defined, still suggesting that
TNFi cycling might offer further gain in clinical control
when a first TNFi failed to obtain the target. Anyway, from
available scientific evidence, some considerations about
this topic should be derived for the decision making pro-
cess: as demonstrated in real life settings, clinical response
tends to decline with the increasing number of previous
TNFis adopted and, in addition, the reason for discontinu-
ation of the first TNFi seems to affect the response to the
second one [6]. Moving from this background and dealing
with this relevant definitive gap in the existing treatment
recommendations, we retrieved available literature evi-
dence on the clinical performance (efficacy and safety) of
cycling vs swapping strategies in RA patients failing TNFi
therapy, in order to eventually derive more definitive
conclusions.
Methods
The literature review was conducted through PubMed and
EMBASE databases to identify all English-language art-
icles fitting the pre-specified topic of cycling
(Intervention, I) vs swapping strategies (Comparison, C)
with respect to efficacy and safety (Outcomes, O) in
adult RA patients (Population, P) failing a TNF inhibitor
(as first or subsequent line of treatment), regardless of
the underlying reason (inefficacy, primary or secondary,
or AEs). The literature review was extended from the
2013 update of the EULAR RA recommendations (8 April
2013) up to 15 January 2016, using appropriate key words
and Medical Subjects Headings for disease (RA) and
bDMARD names (infliximab/IFX, etanercept/ETA, adali-
mumab/ADA, golimumab/GOL, certolizumab pegol/CZP,
abatacept/ABA, rituximab/RTX, tocilizumab/TCZ). The re-
search was performed either by crossing each single TNFi
with every non-TNF bDMARD or by considering all TNFi
agents as a class vs non-anti-TNFs single agents. The
EMBASE search was carried on through population, inter-
vention, comparison and outcome and also advanced
strategies. Additionally, the bibliography of relevant art-
icles was hand-searched for identification of other poten-
tially suitable studies. The research was designed and
performed by one author (M.T.). All available scientific evi-
dence (Table 2) coming from meta-analyses, randomized
controlled trials (RCTs), national registries of biologics and
national healthcare databases has been considered for
data extraction, whenever considering clinical efficacy
endpoints as primary outcomes; safety issues were
TABLE 1 Overview across existing recommendations on the cycling vs swapping topic in RA
Caporali et al. [2] Italian
Recommendations
In patients with inefficacy or adverse events to the first TNF antagonist agent, a treatment
either with a second TNF antagonist or with another biologic with a different MoA is
recommended.
Switching from a second to a third TNF antagonist is not recommended.
In patients failing to respond to a second TNF antagonist, other biologics with different MoA
should be considered.
In patients failing to respond to three (or more) biologic drugs, an attempt with another biologic
drug might be helpful.
Smolen et al. [3] EULAR
Recommendations
If a first biologic has failed, patients should be treated with another biologic. If a first TNF-a
inhibitor has failed, patients may receive another TNF-a inhibitor or a biologic with another
mode of action.
TNF-a inhibitors (i.e. adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and
biosimilars), abatacept, tocilizumab and, under certain circumstances, rituximab are essen-
tially considered to have similar efficacy and safety. If the first biologic fails, any other biologic
may be used.
Singh et al. [4] ACR
Recommendations
If disease activity remains moderate or high, despite use of a single TNF-a inhibitor, use a non-
TNF biologic over another TNF-a inhibitor.
If disease activity remains moderate or high despite use of multiple (>2) sequential TNF-a
inhibitors, first use a non-TNF biologic over another TNF-a inhibitor or tofacitinib.
Smolen et al. [5] EULAR
Recommendations
If a bDMARD or tsDMARD has failed, treatment with another bDMARD or a tsDMARD should be
considered; if one TNF inhibitor therapy has failed, patients may receive another TNF inhibitor
or an agent with another mode of action.
bDMARD: biologic DMARD; MoA: mode of action; tsDMARD: targeted synthetic DMARD.
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evaluated as secondary outcomes. Narrative reviews, edi-
torials, scientific conference abstracts and case reports
have been excluded from this work. The hierarchy of
study types was indicated by levels of evidence as sug-
gested by the Oxford Centre for Evidence-based
Medicine (http://www.cebm.net/oxford-centre-evidence-
based-medicine-levels-evidence-march-2009/).
Preliminary statements based on available results have
been presented in line with their level of evidence, dis-
cussed, eventually reformulated and voted through a
Delphi method during a national consensus of a panel of
Italian rheumatologists. In this article, all the steps dealing
with the swap vs switch strategy will be presented. We
followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines for preparing the
article (http://www.prisma-statement.org/).
Results
General results
Globally, 12 out of 365 full-text articles dealing with
cycling vs swapping strategies in adult RA patients failing
at least one TNFi were selected for final evaluation [718].
Three studies had been conducted in Japanese popula-
tions: one of them, from the REAL Registry, considered
only safety issues between tocilizumab (TCZ) and TNFi in
patients failing previous unspecified bDMARDs (in 71 and
11% of patients, respectively, in the two groups) [11, 13,
15]. This study was subsequently deleted from the final
analysis for incomplete and unavailable relevant inform-
ative data [11]. One report from Navarro-Coy was a study-
protocol with no available results at the date this article
was submitted [14]. Supplementary Fig. S1 shows the
corresponding article flow-chart.
Background data pro-cycling
Several uncontrolled studies suggested benefit in switch-
ing between TNFis [6, 1926, 28]. The rationale for switch-
ing between different TNFis was strengthened by a large,
randomized, industry-led efficacy study comparing goli-
mumab (GOL) with placebo (GO-AFTER trial) [29]. This
phase III study involved 461 patients, who had previously
received and either failed or were intolerant to one or more
TNFis, that were randomized to placebo or subcutaneous
GOL 50 or 100 mg every 4 weeks. Significantly higher
ACR20 response rates at week 14 were observed in the
50 and 100 mg GOL groups compared with the placebo
group (35 and 38% vs 18%, respectively) [29]. One of the
first trials addressing the issue of switching between
TNFis was the open-label multicentre Research in Active
RA focusing on the effectiveness of adalimumab (ADA)
among both TNFi-naı¨ve and TNFi-experienced patients.
Of the 6610 patients enrolled, 5711 had never been trea-
ted with a TNFi, while 899 had received prior treatment
with etanercept (ETA) and/or infliximab (IFX) (591 patients
IFX only, 188 ETA only), with 120 patients already failing
either IFX or ETA. After 12 weeks of open label treatment
with ADA, statistically significant and clinically important
improvements from baseline occurred in all measures of
RA activity in prior TNFi-treated patients as well as in
naı¨ve patients: ACR20 response was achieved by 60%
of TNFi-experienced patients and 70% of TNFi-naı¨ve pa-
tients, thus suggesting the efficacy of cycling in this real
life setting. ADA effectiveness varied by the reason for
discontinuation of the prior TNFi, with the highest re-
sponse rate in patients who had been intolerant to prior
TNFi and with the lowest effectiveness in those patients
stopping TNFi for primary non-response. Moreover, ADA
was effective when used as the third TNFi too, with 46%
among 120 difficult-to-treat patients achieving an ACR20
response. More recently, similar results came from the
Realistic study, which investigated the efficacy and
safety of certolizumab pegol (CZP) in a broad population
of RA patients, resembling those commonly seen in clin-
ical practice, that is subjects with active, inadequately
controlled disease, irrespective of disease duration and
using a broad range of previous and current medications,
including previous TNFi treatment [30]. Of 1063 enrolled
patients, 37.6% had previously been treated with TNFi.
Globally, primary and secondary endpoints were more
frequently achieved in patients in the active arm (CZP),
with ACR20 response rate at week 12 being 51.1% com-
pared with 25.9% for placebo (P< 0.001) and ACR50 and
ACR70 response rates 26.6 and 12.9% for the CZP group
compared with 9.9 and 2.8% for placebo, respectively
(P< 0.001 for each comparison). CZP efficacy was con-
sistent across the subgroups, even when stratified by pre-
vious TNFi use, concomitant use of MTX and disease
duration. Specifically, ACR20 response rates were numer-
ically higher in patients without previous TNFi use than in
TABLE 2 Search strategy and results
Database Search-strategy Retrieved results Selected number (Authors)
EMBASE #1 AND limits 178 6 (Rotar Z, Harrold LR, Emery P, Manders SKM,
Sakai R, Backhaus M)
PubMed
#2 AND limits
#3 AND limits
#4 AND limits
#5 AND limits
36
79
26
45
1 (Hirabara S)
1 (Navarro-Coy NC)
1 (Hirabara S)
5 (Emery P, Kobayakawa T, Hirabara S, Favalli EG, Kim HL)
Hand-made search 1 1 (Harrold LR)
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those with previous TNFi use, although the treatment
interactions were not significant. Similar proportions of
CZP patients previously receiving one or two TNFis
achieved ACR20 response rates at week 12 (46.7 vs
48.2%, respectively), regardless of whether they received
ADA (45.0%), ETA (52.4%) or IFX (46.4%). In addition to
these data, more recently (out of the time frame of our
systematic search) the first head-to-head trial in TNFi-
experienced RA patients has been published, showing a
good efficacy of cycling to a second TNFi even after pri-
mary insufficient response to the first one. The
EXXELERATE study is the first prospective, single blind
(double blinded to week 12 and investigator blinded there-
after) trial assessing in RA patients on MTX background
firstly the efficacy of CZP compared with ADA with a pri-
mary superiority end point at 12 weeks and 2 years, sec-
ondly the comparative efficacy of cycling (from CZP to
ADA and viceversa) in primary non-responders at week
12 without a wash-out period [31]. The results in the pre-
defined analyses showed no superiority of CZP at the
short-term and long-term endpoints, along with a compar-
able safety profile over 2 years. Importantly, in this study,
among patients with a primary inadequate response to the
first TNFi, a similar proportion of subjects responded after
cycling to a second TNFi: 58% of patients switching to
CZP and 62% of patients switching to ADA became re-
sponders 12 weeks later, thus providing additional clinical
evidence of the efficacy and safety of an immediate switch
to a second TNFi in a primary TNFi inadequate responder
population. Such uncontrolled and controlled data from
real life and clinical trials settings confirm that cycling
strategy is a suitable approach in patients failing one or
more TNFis, with a general trend of better clinical gain in
first-switcher patients rather than in subjects not respond-
ing to two or more TNFis.
Background data pro-swap
Several observational studies in RA patients report com-
parative data about cycling and swapping [mainly regard-
ing rituximab (RTX)] strategies from a real life setting.
Trends of better effectiveness in favour of RTX come
from the majority of them, demonstrating significantly
better clinical and functional results compared with the
adoption of a second or third TNFi [3235]. From the
Danish DANBIO register, comparative data on drug sur-
vival, disease activity and clinical response between ABA
and TCZ in RA patients failing at least one TNFi (>90%
patients) have been reported: a good or moderate EULAR
response was achieved in570% of patients treated with
both non-TNFi agents for 24 weeks in routine care, but
without any comparison with a second course of TNFi
[36]. At the time of preparing this article, a first head-to-
head observational trial comparing the efficacy of swap-
ping strategy compared with cycling in TNFi inadequate
responders showed that a non-TNF biologic agent was
more effective in achieving a good or moderate disease
activity at 24 weeks than a second TNFi [37]. In this trial, a
total of 300 RA patients with an insufficient response to
TNFi were included in a 52-week multicentre, pragmatic,
open-label RCT, and randomized to receive a second
TNFi (different from the first) or a different MoA
bDMARD (23% ABA, 28% RTX and 48% TCZ). At week
24, 69% in the non-TNF group and 52% in the second
TNFi group achieved a good or moderate EULAR re-
sponse with an odds ratio (OR) of 2.06 (95% CI: 1.27,
3.37; P = 0.004) in favour of swapping strategy. With sev-
eral limits in mind (lack of blinding of participants, some
bDMARDs such as GOL not allowed, unpowered for indi-
vidual drug differences, bDMARD monotherapy in at least
40% of cases), these results seem to support the choice
of a non-TNF biologic agent after a first TNFi failure.
Results pro-swap
In line with the pre-specified limits of the performed sys-
tematic review, data supporting a swapping strategy are
limited in terms of both quality and quantity (Table 3). The
vast majority of data comes from open label retrospective
or prospective observational trials. In an Italian retrospect-
ive monocentric analysis, among 201 RA non-responder
patients to the first TNFi (mainly due to non-toxic causes,
but with no specification of primary vs secondary non-re-
sponse), survival on therapy with a second line bDMARD
was significantly higher in the swapping than in the cycling
group [16]. After adjustment and matching for propensity
score, probability of treatment retention in the swapping
group was significantly higher (hazard ratio = 2.258, 95%
CI: 1.507, 3.385), even after stratification according to the
reason for the first TNFi discontinuation. No significant
differences emerged when comparing the retention rates
of different MoA drugs in the swapping group, even if limi-
tation due to the paucity of patients in each single thera-
peutic group might have affected the power of the results.
In the multicentre prospective real-life analysis SWITCH-
RA by Emery and coauthors, among 728 RA patients
stopping the first TNFi (204 for primary inefficacy, 332
for secondary inefficacy, 168 due to AEs, 13 for other
reasons), the 6-month effectiveness was significantly
better when swapping to RTX rather than cycling to a
second TNFi: change in DAS28 was substantially greater
in patients starting RTX than a second course of TNFi,
especially in patients failing the first TNFi due to inefficacy
[9]. On the contrary, in cases of failure of the first TNFi for
AEs, switching to a second TNFi or swapping to RTX
seem to provide similar medium-term clinical benefits.
Stratified analysis according to serotype (double sero-
positive patients for RF and ACPA) results in different per-
formance of swapping vs switching strategy according to
the different subsets of patients: seropositive patients fail-
ing the first TNFi due to inefficacy could benefit more from
RTX than from a second TNFi course; seropositive pa-
tients failing the first TNFi for AEs could gain similar bene-
fits form RTX or TNFi; seronegative patients failing the first
TNFi, regardless of the reason, could gain similar benefits
from RTX or a second TNFi. Regarding safety issues, the
overall incidence of AEs and serious AEs was similar in the
two groups. Similarly to most non-interventional studies,
this open-label, observational study had the limitation of
substantial missing data. Because the number and timing
https://academic.oup.com/rheumatology vii45
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of visits were left to the investigators’ discretion, limited
data were available to implement most of the imputation
methods appropriate to handle the withdrawal. However,
the overall results are broadly in agreement with recent
reports from national European registries [3840].
Considering TCZ, in the multicentre retrospective analysis
by Backhaus, TCZ both as mono- or combo-therapy with
csDMARDs was significantly better than TNFi as mono-
combo-therapy in 1603 patients failing a csDMARD or a
previous course of TNFi in terms of achievement of DAS28
remission at 12 weeks (pre-specified primary outcome of the
study). In the specific subset of previous TNFi failing pa-
tients, the pre-defined target of clinical remission was ob-
tained in 41% in TCZ + csDMARDs vs 19% in the second
TNFi + csDMARDs (P< 0.001). Globally, TCZ monotherapy
was more efficacious than TNFi monotherapy in patients
failing a previous csDMARD or a first TNFi, considered as
a global population (DAS28 remission 37.2% vs 30.2%, re-
spectively, P< 0.001). Similar results in favour of TCZ vs
another TNFi (cycling strategy) were obtained with other out-
comes not including acute phase reactants, such as mean
Clinical Disease Activity Index (CDAI) difference from base-
line to 3 months, and with patient-reported outcomes, such
as Visual Analogue Scale for Patient’s Global Assessment
(VAS-PGA), VAS-pain and morning stiffness, thus avoiding
eventual over-results due to TCZ effects on serum inflam-
matory biomarkers. As a limit of this study, the authors
stated that long-term results are obviously required to con-
firm such short-term data, which represent the cut-off time
point to assess primary response to bDMARDs in accord-
ance with EULAR guidelines [3]. Anyway, in accordance with
this, it seems that in the short term TCZ might offer higher
clinical efficacy compared with TNFi after previous TNFi fail-
ure, with no current information about the maintenance of
the benefits over time.
Additional data regarding RTX and ABA in TNFi failure
patients come from two retrospective reports from the
CORRONA registry by Harrold et al.: in the stratified-
matched population (failures of at least one TNFi), ABA
offered no advantage (mean CDAI modification, ACR20/
50/70 responses, HAQ improvement) over a further TNFi
both at 6 and 12 months of follow-up, while RTX users had
significantly higher probability of achieving low disease
activity, ACR20 response and HAQ improvement [8, 18].
Overall, available data seem to confirm that changing
mode of action might be a better option, especially in
seropositive patients failing a first TNFi due to inefficacy
(results in favour of RTX vs another TNFi) or in patients
requiring bDMARD monotherapy (results in favour of TCZ
monotherapy vs another TNFi monotherapy).
Results pro-similar performance cycling vs swapping
In the absence, within the pre-specified time frame of the
review, of direct head-to-head trials comparing bDMARDs
with different MoA in TNFi failure patients, indirect meta-
analysis has emerged as an accepted and valid method-
ology for comparing drugs with each other using a
common comparator (placebo or a synthetic DMARD).
The best quality data indirectly comparing switching vs
swapping strategies in TNFi failures come from a network
meta-analysis (Tables 3 and 4), which pooled results from
four randomized placebo-controlled trials involving quite
homogeneous target populations: the GO-AFTER trial,
the RADIATE trial, the REFLEX trial and the ATTAIN trial
[17]. All these studies, even if with different proportions,
included long-standing RA patients failing one or more
TNFis (ADA, IFX, ETA) due to inefficacy or AE, mostly
used in combination with csDMARDs. Globally, the pro-
portion of patients who achieved ACR20 was highest for
TCZ (62.4%; 95% CI: 49.9, 74.0%), followed by RTX
(47.0%; 95% CI: 37.7, 56.6%), ABA (43.7%; 95% CI:
32.9, 55.4%) and GOL (32.1%; 95% CI: 22.3, 44.0%),
and lowest for placebo (15.5%; 95% CI: 12.8, 18.5%).
Similarly, the ACR50 was higher for TCZ and lower for
placebo; RTX had the highest proportion of patients
achieving ACR70. According to the clinical evidence to
date, these findings suggest that non-TNF biologic
agents such as RTX, ABA and TCZ are more effective
than TNFi for the treatment of RA patients failing a first
TNFi. However, no definite conclusions can be drawn in
this setting due to many limitations: short follow-up period,
lack of safety analysis along with efficacy data, absence of
studies involving cycling to a TNFi different from GOL, lack
of sub-analysis stratified by number of previous TNFis. A
previous indirect meta-analysis by Schoels involving the
same trials underlined the similarity in the ACR50 and 70
response rates for all agents (ABA, GOL, RTX and TCZ),
suggesting that all biologic drugs have comparable effi-
cacy in TNFi-failing RA patients, when considering relevant
clinical response [41]. In addition, in line with this first
report, GOL presented significantly fewer AEs with respect
to indirect comparators. Moreover, in sub-analysis strati-
fied by the number of previous TNFi failures, indirect com-
parison of response rates between GOL and TCZ found
very similar rates after one, two or three TNFis, although
there was a trend toward significance after three TNFis: the
small number of patients in this subgroup represents an
important limit of this part of the study. Besides these two
meta-analyses, a study by Manders and colleagues [10]
published in 2015 tried to compare the effectiveness and
cost-effectiveness of three biologic treatments with differ-
ent MoA in RA patients in which TNFi therapy has failed. In
this pragmatic multicentre randomized trial, 139 RA pa-
tients failing a first TNFi (due to ineffectiveness or AEs)
were allocated to a second TNFi agent (50 patients) or to
i.v. ABA or RTX (43 and 46 patients, respectively); TCZ was
not yet licensed at the time of the study and thus not
analysed. There were no significant differences between
the three groups with respect to multiple RA outcomes
at 1 year of follow-up (primary outcome: DAS28 and sec-
ondary outcomes: HAQ and SF-36); however, the analysis
revealed that RTX therapy was significantly more cost-ef-
fective than both ABA and TNFi. In other words, all treat-
ment options were similarly clinically effective; however,
when costs were factored into the treatment decision,
RTX was the best option available for patients whose
first TNFi treatment failed. However, generalization of
these cost-effective analyses to other countries should
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be considered carefully, due to possible differences in
pharmaco-economic issues. No differences resulted in
the performance of a second course of bDMARD in line
with cycling (toward ETA) or swapping (to TCZ or ABA) in
89 Japanese RA patients stopping a first TNFi mAb (ADA
or IFX) due to inadequate response: similar retention rate
and mean CDAI values were observed among patient
groups [13]. In another Japanese study, retention rates of
a second biologic treatment were compared by the type of
first TNFi and second biologic agents: 169 RA patients
who failed a first course of TNFi therapy from the
Tsurumai Biologics Communication Registry (ADA/IFX,
ETA) received a different TNFi or TCZ as a second biologic
agent [15]. Adjusting for confounders, drug retention rate
of the second biologic agent after switching from IFX/ADA
was significantly higher with ETA (90.0%) and TCZ (94.7%)
than with ADA/IFX (59.3%); drug retention rate of the
second biologic agent after switching from ETA was sig-
nificantly higher with TCZ (75.9%) than with ADA/IFX
(46.3%). In other words, switching from anti-TNF mAb
(ADA/IFX) to soluble anti-TNF receptor (ETA) leads to
better results than vice versa: as the authors stated, this
might be due mainly to the well-known lesser immunogen-
icity of ETA, thus inducing lower incidence of anti-drug
antibodies. Another reason of higher probability of failure
after switching from ETA to ADA/IFX rather than vice versa
might rely on its additional targeting against lymphotoxin-a
(TNF-b), besides TNF-a. Differences in ADAs detection be-
tween Japanese and Caucasian patients, possibly related
to different MTX dosage adoption and/or different ethnic
background, might in part suggest caution when interpret-
ing such results.
Conclusions
No standardized and homogeneous approach has been
proposed by existing recommendations for RA patients
failing a first TNFi. Several bDMARDs with different MoA
are now available for the treatment of this subset of pa-
tients, with no proven direct comparison (at the time this
systematic review was performed) between alternative
options (cycling vs swapping strategies). Moving from
this gap in our knowledge, we performed a systematic
review trying to update evidence-based information sup-
porting the decision-making process. According to
scientific data on this relevant topic published within the
pre-defined temporal limits, thus combined and enriched
by a national consensus of expert rheumatologists, pre-
liminary statements regarding cycling vs swapping strate-
gies in RA patients failing the first course of TNFis might
be formulated as indicated in Table 4. Thus, up to now,
mainly from indirect comparison from RCTs and real life
experiences, both strategies might be adopted in cases of
first TNFi failure, with some evidence suggesting better
performance of swapping over switching.
Reasearch agenda
Since our work was submitted, further evidence had been
published on such a relevant topic involving emerging and
progressively marketed drugs, such as biosimilars and
targeted systemic DMARDs, namely tofacitinib and bari-
citinib. Specifically, in a systematic review by Singh and
coauthors, results have been reported from a network
meta-analysis involving 12 trials dealing with subsequent
therapies in RA patients failing previous TNFi [42]. Patients
were stratified by biologic type (anti-TNF vs non-anti-TNF
biologic agents), DMARD background (bDMARD mono-
therapy vs MTX combo-therapy) and bDMARD dose
(standard vs high dose). Considering clinical outcomes,
on background MTX and compared with non-TNF
agents, TNF biologics were not associated with any stat-
istically significant or clinically meaningful difference in the
odds of both clinical remission (OR = 0.75, 95% CI: 0.04,
26.4) and ACR50 response (OR = 0.51, 95% CI: 0.18,
1.54) [42]. Similarly, non-statistically significant differences
were seen when comparing tofacitinib to non-TNF (for
TABLE 4 Final statements
Final statement
Level of
evidence
Level of
agreement (%)
In case of failure to one or more TNFis (regardless of the reason), switching to another TNFi or
swapping to a different MoA agent (+ csDMARDs) could provide similar relevant clinical
(ACR50/ACR70) control.
1A 91
Treatment with RTX after TNFi failure might be associated with higher prevalence of infusion
reactions respect to i.v. TCZ and ABA.
1A 75
The use of GOL after previous TNFi failure might be associated with less occurrence of AEs
with respect to non-anti-TNF bDMARD agents.
1A 86
In seropositive patients (RF and ACPA+) failing a first TNFi due to inefficacy, swapping to RTX
could provide more clinical benefits than switching to a second TNFi. In seropositive pa-
tients, failing a first TNFi due to AEs, similar benefits could be obtained with either RTX or a
second TNFi.
2 B 95
Seronegative (RF and ACPA) patients failing the first TNFi (regardless of the reason) could
gain similar benefits using either a second TNFi or RTX.
2 B 91
Clinical response at 12 weeks in patients with inadequate response to TNFi has been reported
to be higher for TCZ (as mono- or combo-therapy) than TNFis.
2 B 97
ABA: abatacept; AE: adverse event; bDMARD: biologic DMARD; csDMARD: conventional synthetic DMARD; GOL: golimumab;
MoA: mode of action; RTX: rituximab; TNFi: TNF inhibitor; TCZ: tocilizumab.
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ACR50 response OR = 0.65, 95% CI: 0.23, 1.86) or TNFi
(for ACR50 response OR = 1.26, 95% CI: 0.36, 4.40). No
studies examined radiographic progression outcome, so
that indirect comparisons on structural endpoints should
not be evaluated. Considering safety issues, no significant
advantage was reported for one agent over another.
Moreover, in a real life setting, Li et al. [43] demonstrated
that only ADA could be as efficacious as non-TNF
bDMARD after ETA failure in a large multinational RA
population. Nevertheless, TNFis as a class were overall
less effective than a second non-TNF-a biologic (EULAR
good response rate 56.0 vs 64.4%, P < 0.05 and CDAI
score change 6.3 vs 7.3, P= 0.06, respectively). Such a
relevant issue could be finally resolved by the future re-
sults of the SWITCH trial, whose protocol design has been
already published and that includes also global cost-ef-
fectiveness evaluation among secondary outcomes [14].
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